Propanc Advances PRP After Strong Preclinical Pancreatic Cancer Results
Melbourne, Australia – August 27, 2026 Propanc Biopharma announced new preclinical and early translational data for PRP in pancreatic...
Propanc Biopharma
Advertisement
Propanc Biopharma Advances PRP as a Novel Approach for RAS-Driven Cancers
MELBOURNE, Australia, August 12, 2026 Propanc Biopharma, Inc. highlighted the potential of its investigational proenzyme therapy PRP as a...
Propanc Biopharma Reports Strong Preclinical PRP Results
MELBOURNE, Australia, August 6, 2026 Propanc Biopharma announced compelling preclinical and early translational findings for its lead investigational therapy...
Advertisement
